1-3 of 3
Rob C.M. de Jong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia

Georgia Koutsoumpli, Dyantha I. van der Lee, Nina C. Groenland, M. Willy Honders, Rob C.M. de Jong, Renate S. Hagedoorn, Hendrik Veelken, Peter A. van Veelen, Dominik Lock, Mirjam H.M. Heemskerk, J.H.Frederik Falkenburg, Ian Johnston, Marieke Griffioen
Journal: Blood
Blood (2022) 140 (Supplement 1): 10243–10244.
https://doi.org/10.1182/blood-2022-158195
Published: 2022
Journal Articles

The First Functional HLA-a*01:01-Restricted EBV-LMP2-Specific T-Cell Receptors for TCR Gene Therapy of Patients with EBV-Associated Type II/III Malignancies

Wesley Huisman, MSc, Ilse Gille, Lieve E. van der Maarel, Lois Hageman, Rob C.M. de Jong, PhD, Derk Amsen, PhD, Fred Falkenburg, MD PhD, Inge Jedema, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4448.
https://doi.org/10.1182/blood-2019-123736
Published: 2019
Journal Articles

Isolation and Validation of the First Functional HLA-a*01:01 Restricted EBV-LMP2 Specific T Cells for Treatment of EBV Associated Type II/III Lymphomas

Wesley Huisman, MSc, Lieve E. van der Maarel, Lois Hageman, Rob C.M. de Jong, Derk Amsen, PhD, J.H. Frederik Falkenburg, MD PhD, Inge Jedema, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1578.
https://doi.org/10.1182/blood-2018-99-116127
Published: 2018